Hungary: A New Model of Care
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Address: Zolyomi ut 23 H-1118 Budapest,Hungary
Tel: +36 1 391 4455
Abiomics Europe Ltd.
„Advanced Biostatistics and Intelligence for the Omics”
Abiomics Europe Ltd. is a technology startup company that was founded in 2009 by bioinformatics and biomedical researchers along with investors. The cooperation between the Semmelweis University, Department of Genetics, Cell- and Immunobiology and the Budapest University of Technology and Economics, Department of Measurement and Information Systems started in 2005 and led to the establishment of the company.
The 5 years of cooperation and joint projects made it clear that modern life science research and development is not possible anymore without advanced information technology support. The GenaGrid consortium was founded in 2008 with the support of the National Office for Research and Technology when new academic and industry partners joined the research group and aims to develop various bioinformatics services. Abiomics Europe Ltd. is the company responsible for the utilization for the intellectual properties of the consortium and has all the exclusive rights for the developed technologies. Abiomics Europe drives the business development, market research and marketing activities for the consortium.
The GenaGrid research group and Abiomics Europe employs almost 30 informaticians and biomedical researchers. The group engages the technologies and software in Asthma and ALL research. The GenaGrid research group operates a genomics lab and the most powerful grid supercomputer dedicated for life science research in Hungary with 512 CPUs (March 2010).
Abiomics provides to their customers advanced information technology support.
One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If…
Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have…
Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence…
While pharmaceutical products and healthcare financing dominate the majority of discussions surrounding the improvement of health outcomes, health literacy still remains a core issue that, if left unaddressed, may vary…
Preventive healthcare and health literacy are core issues in Hungary that, if left unaddressed, may hinder the country’s ability to push its health agenda forward and create a more sustainable…
Smaller pharma companies in Hungary are looking to new unconventional methods of OTC promotion to sidestep the country’s somewhat restrictive reimbursement scheme and compete with major players in the market. Especially in…
The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges…
LEO Pharma Hungary’s Andrea Bondár demonstrates the significance of adopting non-traditional methods of promotional activities, and defines how a true intent on understanding the psyche of patients suffering from chronic…
Anita Ordog, GM of Angelini Hungary, discusses the affiliate’s history in the country, their expanding OTC and specialty products portfolio, targeted marketing and sales strategies, and Angelini’s challenging entrance into…
Dr. Lívia Ilku, director of Hungary’s main domestic pharmaceutical manufacturers’ association (MAGYOSZ), describes the current priorities of its member companies and the key factors for success in Hungary; specifically innovation…
Prof. Dr. István Vályi-Nagy, Director General of the United St. Istvan and St. Laszlo Hospitals, shares his insights on running one of the largest hospitals in Hungary and the challenges…
The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic…
See our Cookie Privacy Policy Here